<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629468</url>
  </required_header>
  <id_info>
    <org_study_id>A/28/EC/337/2021</org_study_id>
    <nct_id>NCT05629468</nct_id>
  </id_info>
  <brief_title>Comparing Efficacy of Azithromycin and Probiotics for Treatment of Acne Vulgaris</brief_title>
  <official_title>Comparing Efficacy of Azithromycin and Probiotics for Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pak Emirates Military Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pak Emirates Military Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the goal of this clinical trial is to measure the efficacy of probiotics for treatment of&#xD;
      acne vulgaris, to compare it with azithromycin and to measure the synergistic effect of&#xD;
      azithromycin and probiotics for treatment of acne vulgaris&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      this study aims to answer this research question: in patients of acne vulgaris, is use of&#xD;
      probiotics as efficacious as azithromycin in treating acne lesions &amp; improving quality of&#xD;
      life? total 75 patients were divided into 3 groups. group A received azithromycin, group B&#xD;
      received probiotics and group C received both drugs. a topical cream was also advised to all&#xD;
      groups. outcome was measured as reduction in total lesion count and improvement in patients'&#xD;
      quality of life via reduction in Dermatology Life Quality Index score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Actual">August 31, 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change or reduction in the Total Lesion Count</measure>
    <time_frame>at start of the study (baseline), 2 weeks (1st follow up visit), 4 weeks (2nd follow up visit), 8 weeks (3rd follow up visit) and 12 weeks (4th follow up visit).</time_frame>
    <description>number of acne lesions are counted at every follow up to see whether lesions are reduced than the baseline or not</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change or reduction in the Dermatology Life Quality Index score</measure>
    <time_frame>at start of the study (baseline) and 12 weeks (last follow up visit).</time_frame>
    <description>improvement in patients' quality of life was assessed to see whether the score has been reduced than the baseline score or not. it was assessed by a 10-item self assessment questionnaire i.e Dermatology Life Quality Index. the score ranges between 0 to 30. higher score means worst outcome and the lower score means better outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Azithromycin and Topical</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group A (n=25) received tab. azithromycin 250mg oral on alternate days and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotics and Topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group B (n=25) received Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin and Probiotics and Topical</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>combination group C (n=25) received tab. azithromycin 250mg oral on alternate days, Probiotic sachet oral once a day everyday and topical cream benzoyl peroxide 4% twice a day daily for a period of 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>antibiotic</description>
    <arm_group_label>Azithromycin and Probiotics and Topical</arm_group_label>
    <arm_group_label>Azithromycin and Topical</arm_group_label>
    <other_name>&quot;Zetro&quot; by &quot;Getz Pharma&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Formula</intervention_name>
    <description>probiotics</description>
    <arm_group_label>Azithromycin and Probiotics and Topical</arm_group_label>
    <arm_group_label>Probiotics and Topical</arm_group_label>
    <other_name>&quot;Hi-Flora&quot; by &quot;Unicare Bioceuticals&quot;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl Peroxide 4 % Topical Cream</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Azithromycin and Probiotics and Topical</arm_group_label>
    <arm_group_label>Azithromycin and Topical</arm_group_label>
    <arm_group_label>Probiotics and Topical</arm_group_label>
    <other_name>&quot;Benoxyl&quot; by &quot;Glitz pharma&quot;</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed Patients of Mild and Moderate acne&#xD;
&#xD;
          -  Aged between 15 and 35 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe acne or any systemic inflammatory disease&#xD;
&#xD;
          -  Other oral treatment for acne&#xD;
&#xD;
          -  Allergic to any drug being used in the study&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  PCOs&#xD;
&#xD;
          -  Any drug which can interact with azithromycin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akbar W Syed, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Riphah International University, Islamabad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PEMH</name>
      <address>
        <city>Rawalpindi</city>
        <state>Punjab</state>
        <zip>46000</zip>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>November 30, 2022</last_update_submitted>
  <last_update_submitted_qc>November 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pak Emirates Military Hospital</investigator_affiliation>
    <investigator_full_name>Mushayada Irshad</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

